DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Interim Report
BB Biotech AG publishes its interim report
22-Jul-2022 / 07:00 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Ad hoc announcement pursuant to Art. 53 LR
July 22, 2022
BB Biotech AG publishes its interim report
BB Biotech AG (ISIN CH0038389992) today published its interim report as at June 30, 2022, which covers the results of its business activities for the first six months of 2022.
Based on the consolidated accounts of BB Biotech AG, net loss for the period ended June 30, 2022 amounted to CHF 533 mn (profit of CHF 349 mn in H1 2021). In the second quarter a loss of CHF 233 mn (profit of CHF 129 mn in the corresponding period of the previous year) was incurred. For an investment company, the reported profit reflects the performance of the stocks that it holds in its portfolio.
BB Biotech AG’s interim report as at June 30, 2022 is available under report.bbbiotech.ch/Q222 or www.bbbiotech.com.
Company profile
BB Biotech AG is an investment company with its registered office in Schaffhausen/Switzerland and listed on the Swiss, German and Italian stock exchanges. It has invested in innovative drug developers headquartered primarily in the US and Western Europe. BB Biotech is one of the world’s largest investors in this sector. The competent Board of Directors with its long-standing experience set the investment strategy and guidelines. Investment decisions are taken by the experienced investment management team of Bellevue Asset Management AG based on their extensive investment research.
22-Jul-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Language:
English
Company:
BB BIOTECH AG
Schwertstrasse 6
8200 Schaffhausen
Switzerland
Phone:
+41 52 624 08 45
E-mail:
info@bbbiotech.com
Internet:
www.bbbiotech.ch
ISIN:
CH0038389992
WKN:
A0NFN3
Listed:
Regulated Market in Frankfurt (Prime Standard); Mailand, SIX
BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Companyâs portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.
BB BIOTECH AG 
